Effective January 1, 2016, new precertification requirements will apply to our
commercial and Medicare Advantage HMO and PPO members for the seven medical
benefit drugs listed below:
-
Adagen® (pegademase bovine)
-
Blincyto® (blinatumomab)
-
Cyramza® (ramucirumab)
-
KanumaTM (sebelipase alfa)*
-
Lemtrada® (alemtuzumab)
-
mepolizumab*
-
talimogene laherparepvec*
These changes will be reflected in an updated precertification requirement
list, which will be posted to our website in December, prior to these changes
going into effect. Look for more information about the availability of this new
precertification requirement list in the December 2015 edition of Partners in
Health Update
SM.
*Pending approval from the U.S. Food and Drug
Administration